agilon health Appoints Tim O'Rourke as New CEO and President with Ambitious Stock Price Performance Incentives

summarizeSummary

agilon health has appointed Tim O'Rourke as its new Chief Executive Officer and President, effective May 7, 2026, with a compensation package heavily weighted towards achieving significant stock price targets.

check_boxKey Events

• New CEO and President Appointed

  Tim O'Rourke has been appointed Chief Executive Officer, President, and a Class III Director, effective May 7, 2026.

• Performance-Based Equity Incentives

  Mr. O'Rourke's compensation includes 200,000 performance-vesting restricted stock units (PSUs) tied to stock price targets of $50, $100, and $150 per share.

• Extensive Healthcare Industry Experience

  Mr. O'Rourke brings a strong background from leadership roles at Help at Home, Centene Corporation, Ascension Complete LLC, and Humana, Inc.

• Strategic Leadership Change Amidst Challenges

  This executive appointment is a significant strategic move for the company, which has recently reported substantial losses and faces a NYSE delisting threat.

auto_awesomeAnalysis

This appointment is a critical development for agilon health, especially given its recent financial struggles, including wider losses and a NYSE delisting threat, as detailed in the 2026-02-25 10-K. Mr. O'Rourke's extensive experience in the healthcare industry, coupled with a compensation structure that includes performance-vesting restricted stock units tied to ambitious stock price targets of $50, $100, and $150, signals a strong commitment from the board to a potential turnaround. This move could be a key component of the company's strategy to improve its financial position and address the delisting concerns, following the recent reverse stock split confirmed in the 2026-04-22 DEF 14A.